Across TCGA pan-cancer cohorts, SLC22A10 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SLC22A10’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SLC22A10 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC22A10 is over-expressed in tumor, although a few such as LIHC and LUAD show the opposite, repressed pattern.
LIHC, LUAD, and CHOL are the cancer types where SLC22A10 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC22A10 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.